$2.35
Revenue is down for the last 2 quarters, 27.02M → 25.11M (in $), with an average decrease of 7.0% per quarter
Netprofit is up for the last 5 quarters, -76.28M → -16.84M (in $), with an average increase of 50.2% per quarter
In the last 3 years, Idexx Laboratories, Inc. has given 50.9% return, outperforming this stock by 94.7%
1.28%
Downside
Day's Volatility :6.07%
Upside
4.86%
60.85%
Downside
52 Weeks Volatility :65.28%
Upside
11.32%
Period | Standard BioTools Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 34.62% | -0.3% | -6.7% |
6 Months | 76.26% | -8.8% | -6.2% |
1 Year | 29.63% | -4.2% | -5.1% |
3 Years | -37.66% | 23.0% | 26.9% |
Market Capitalization | 195.2M |
Book Value | - $1.24 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.6 |
Wall Street Target Price | 0.7 |
Profit Margin | -135.3% |
Operating Margin TTM | -104.29% |
Return On Assets TTM | -19.56% |
Return On Equity TTM | -110.62% |
Revenue TTM | 96.6M |
Revenue Per Share TTM | 1.23 |
Quarterly Revenue Growth YOY | -5.2% |
Gross Profit TTM | -1.4M |
EBITDA | -97.4M |
Diluted Eps TTM | -1.6 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.01 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Downside of 70.21%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 101.9M | ↓ 2.4% |
Net Income | -60.5M | ↓ 20.33% |
Net Profit Margin | -59.38% | ↑ 13.37% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 113.0M | ↑ 10.82% |
Net Income | -59.0M | ↓ 2.51% |
Net Profit Margin | -52.24% | ↑ 7.14% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 117.2M | ↑ 3.79% |
Net Income | -64.8M | ↑ 9.79% |
Net Profit Margin | -55.26% | ↓ 3.02% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 138.1M | ↑ 17.83% |
Net Income | -53.0M | ↓ 18.17% |
Net Profit Margin | -38.38% | ↑ 16.88% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 130.6M | ↓ 5.47% |
Net Income | -59.2M | ↑ 11.73% |
Net Profit Margin | -45.36% | ↓ 6.98% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 97.9M | ↓ 24.99% |
Net Income | -190.1M | ↑ 220.91% |
Net Profit Margin | -194.08% | ↓ 148.72% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 38.3M | ↑ 34.24% |
Net Income | -9.4M | ↓ 31.89% |
Net Profit Margin | -24.64% | ↑ 23.93% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 26.5M | ↓ 30.74% |
Net Income | -76.3M | ↑ 709.08% |
Net Profit Margin | -287.84% | ↓ 263.2% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 18.8M | ↓ 29.15% |
Net Income | -63.5M | ↓ 16.71% |
Net Profit Margin | -338.39% | ↓ 50.55% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 25.6M | ↑ 36.58% |
Net Income | -29.4M | ↓ 53.69% |
Net Profit Margin | -114.74% | ↑ 223.65% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 27.0M | ↑ 5.36% |
Net Income | -20.8M | ↓ 29.16% |
Net Profit Margin | -77.14% | ↑ 37.6% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.1M | ↓ 7.04% |
Net Income | -16.8M | ↓ 19.2% |
Net Profit Margin | -67.05% | ↑ 10.09% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 287.4M | ↓ 6.22% |
Total Liabilities | 256.4M | ↑ 1.29% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 303.6M | ↑ 5.67% |
Total Liabilities | 231.5M | ↓ 9.7% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 264.8M | ↓ 12.79% |
Total Liabilities | 111.2M | ↓ 51.97% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 324.8M | ↑ 22.64% |
Total Liabilities | 185.7M | ↑ 67.0% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 275.2M | ↓ 15.26% |
Total Liabilities | 180.6M | ↓ 2.74% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 390.3M | ↑ 41.82% |
Total Liabilities | 160.5M | ↓ 11.13% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 275.2M | ↓ 2.47% |
Total Liabilities | 180.6M | ↓ 1.22% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 271.9M | ↓ 1.19% |
Total Liabilities | 249.8M | ↑ 38.32% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 441.1M | ↑ 62.21% |
Total Liabilities | 167.3M | ↓ 33.02% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 414.9M | ↓ 5.94% |
Total Liabilities | 166.4M | ↓ 0.55% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 390.3M | ↓ 5.93% |
Total Liabilities | 160.5M | ↓ 3.54% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 371.7M | ↓ 4.78% |
Total Liabilities | 157.6M | ↓ 1.85% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -24.1M | ↓ 38.43% |
Investing Cash Flow | 17.7M | ↓ 60.85% |
Financing Cash Flow | 29.0M | ↑ 24897.41% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.2M | ↑ 4.58% |
Investing Cash Flow | 4.7M | ↓ 73.28% |
Financing Cash Flow | 57.7M | ↑ 98.85% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -35.2M | ↑ 39.72% |
Investing Cash Flow | -39.3M | ↓ 932.82% |
Financing Cash Flow | 2.8M | ↓ 95.16% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.4M | ↓ 56.21% |
Investing Cash Flow | 40.0M | ↓ 201.71% |
Financing Cash Flow | 20.9M | ↑ 647.56% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -44.1M | ↑ 185.79% |
Investing Cash Flow | -11.9M | ↓ 129.88% |
Financing Cash Flow | 16.0M | ↓ 23.48% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -89.4M | ↑ 102.83% |
Investing Cash Flow | -88.1M | ↑ 637.71% |
Financing Cash Flow | 230.8M | ↑ 1345.94% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.0M | ↓ 26.25% |
Investing Cash Flow | -1.1M | ↓ 32.88% |
Financing Cash Flow | 7.3M | ↓ 25.7% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -15.6M | ↑ 122.65% |
Investing Cash Flow | -868.0K | ↓ 24.19% |
Financing Cash Flow | 18.1M | ↑ 147.7% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -30.0M | ↑ 92.35% |
Investing Cash Flow | -138.2M | ↑ 15826.27% |
Financing Cash Flow | 213.0M | ↑ 1078.19% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -40.2M | ↑ 34.06% |
Investing Cash Flow | 10.7M | ↓ 107.77% |
Financing Cash Flow | 18.1M | ↓ 91.51% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -89.4M | ↑ 122.31% |
Investing Cash Flow | -88.1M | ↓ 920.86% |
Financing Cash Flow | 230.8M | ↑ 1177.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.5M | ↓ 90.51% |
Investing Cash Flow | 43.2M | ↓ 148.97% |
Financing Cash Flow | -2.6M | ↓ 101.11% |
Sell
Neutral
Buy
Standard BioTools Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Standard BioTools Inc | 53.13% | 76.26% | 29.63% | -37.66% | -37.66% |
![]() IDEXX Laboratories, Inc. | -4.78% | 9.47% | 19.05% | 49.34% | 123.92% |
![]() Agilent Technologies Inc. | -13.48% | -24.04% | -7.71% | 30.94% | 90.13% |
![]() Thermo Fisher Scientific, Inc. | -6.25% | -8.21% | -9.4% | 47.2% | 146.9% |
![]() Danaher Corp. | -6.02% | -16.91% | -13.89% | 37.37% | 128.83% |
![]() IQVIA Holdings Inc. | 4.55% | -8.88% | -7.71% | 32.96% | 100.8% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Standard BioTools Inc | NA | NA | NA | -0.01 | -1.11 | -0.2 | 0.0 | -1.24 |
![]() IDEXX Laboratories, Inc. | 55.23 | 55.23 | 7.21 | 9.69 | 0.94 | 0.22 | 0.0 | 10.13 |
![]() Agilent Technologies Inc. | 26.91 | 26.91 | 2.36 | 5.63 | 0.25 | 0.1 | 0.01 | 18.96 |
![]() Thermo Fisher Scientific, Inc. | 34.01 | 34.01 | 4.28 | 23.68 | 0.14 | 0.05 | 0.0 | 109.55 |
![]() Danaher Corp. | 25.0 | 25.0 | 3.24 | 9.38 | 0.14 | 0.06 | 0.0 | 68.31 |
![]() IQVIA Holdings Inc. | 35.62 | 35.62 | 1.48 | 10.42 | 0.18 | 0.05 | 0.0 | 31.98 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Standard BioTools Inc | Buy | $195.2M | -37.66% | NA | -135.3% |
![]() IDEXX Laboratories, Inc. | Buy | $38.9B | 123.92% | 55.23 | 20.38% |
![]() Agilent Technologies Inc. | Buy | $35.3B | 90.13% | 26.91 | 19.09% |
![]() Thermo Fisher Scientific, Inc. | Buy | $201.4B | 146.9% | 34.01 | 13.75% |
![]() Danaher Corp. | Buy | $171.3B | 128.83% | 25.0 | 22.4% |
![]() IQVIA Holdings Inc. | Buy | $37.0B | 100.8% | 35.62 | 7.28% |
Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, the Company strives to increase the quality of life for all.
Organization | Standard BioTools Inc |
Employees | 523 |
CEO | Mr. Vikram Jog |
Industry | Healthcare |
Pennant Park Investment Corp
$5.52
-0.18%
iShares Trust - iShares Investment Grade Corporate Bond BuyWrite Strategy ETF
$33.71
+0.26%
LEMONADE INC
$17.62
+0.51%
INNOVATOR S&P 500 POWER BUFF
$29.83
-0.37%
Remark Holdings, Inc.
$1.21
-9.02%
FIDELITY D&D BANCORP INC
$37.80
-2.11%
IQ MacKay Municipal Intermediate ETF
$24.26
+0.25%
FT CBOE VEST US EQUITY DEEP
$34.72
-0.46%
FIRST TRUST EUROPE
$33.28
-1.26%